TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tryptamine Therapeutics ( (AU:TYP) ) has provided an update.
Tryptamine Therapeutics Limited reported a significant decline in revenue by 57.2% and an increase in losses by 49.4% for the half-year ending December 2024. The financial results reflect a challenging period for the company, impacting its market position and stakeholder confidence, with no dividends declared during this period.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on developing therapeutic solutions. The company is involved in the research and development of treatments, with a market focus on innovative therapies.
YTD Price Performance: -10.0%
Average Trading Volume: 1,869,760
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$45.95M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.